PanC-ASAP, by AbilityPharma

Accelerating Solutions for Pancreatic Cancer

Pancreatic cancer currently only receives 2% of all cancer research funding, leading to an urgent and unmet medical need for investment in developing a safe and effective treatment for patients with this cancer.

Our client, the Catalan biopharmaceutical company Ability Pharmaceuticals SL will start a phase 2b clinical trial in advanced pancreatic cancer patients to investigate their drug  in combination with standard chemotherapy. ABTL0812 has strong potential to treat pancreatic cancer and is a safe and effective treatment for patients.

AbilityPharma’s goal is to conduct this double-blind, placebo-controlled, multicenter phase 2 clinical trial in pancreatic cancer patients to investigate ABTL0812 in combination with FOLFIRINOX. The study will include leading centers in Spain, France, Israel and other European countries. After completing the clinical trial, a licensing agreement will be established with a pharmaceutical company to further develop ABTL0812, with the aim of making it available to patients with pancreatic cancer. Frontline opinion leaders in pancreatic cancer clinical research in Barcelona, France and Israel support the project and will lead the clinical trial in their territories.

With the aim of obtaining financing for this fantastic project, AbilityPharma applied to the January 2020 call of the EIC Accelerator and we are very pleased to announce that they have obtained the financing they needed. The project requested the option of Grant + Equity, which means they have obtained 2.5 million euros as a grant, and 2.5 million euros more as investment and shareholding, managed by the European Investment Bank.

From Aristos we are very proud to have helped AbilityPharma achieve this success and we wish them the best of luck in the development of this project, which is so important for all those who suffer from this terrible disease.